Emily Sauce
Flowood, MSNPI 1639819451
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.0% of the total across 67 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 20.9% — the pattern of someone who eats at a lot of different presentations.
Across 67 payments — averaging $73.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$1K
- AbbVie$769
- Lilly USA, LLC$622
- Janssen Scientific Affairs, LLC$348
- Novartis$321
- Incyte Corporation$264
- plus $2K from 14 others
What the payments were for
- Food & beverage$4,83298%
- Education$992%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 10 | $1,032 |
| AbbVie | 8 | $769 |
| Lilly USA, LLC | 9 | $622 |
| Janssen Scientific Affairs, LLC | 8 | $348 |
| Novartis | 4 | $321 |
| Incyte Corporation | 2 | $264 |
| E.r. Squibb & Sons, L.L.C. | 3 | $234 |
| UCB, Inc. | 2 | $195 |
| Kyowa Kirin, Inc. | 2 | $182 |
| Organon | 4 | $163 |
| Pfizer | 3 | $159 |
| Johnson & Johnson | 3 | $136 |
| Boehringer Ingelheim | 1 | $124 |
| Dermavant Sciences, Inc. | 1 | $113 |
| Galderma Laboratories, L.p. | 2 | $108 |
| Mallinckrodt Hospital Products Inc. | 1 | $92 |
| Sobi, Inc | 1 | $22 |
| Regeneron Healthcare Solutions, Inc. | 1 | $20 |
| Merck | 1 | $14 |
| Almirall LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 19 | $178,456 |
| Dupixent PenDupilumab | 13 | $48,365 |
| Tacrolimus | 28 | $3,938 |
| Ketoconazole | 75 | $1,714 |
| Clobetasol Propionate | 23 | $1,363 |
| CiclopiroxCiclopirox Olamine | 28 | $1,056 |
| Triamcinolone Acetonide | 74 | $929 |
| Fluorouracil | 11 | $685 |
| Clindamycin Phosphate | 14 | $571 |
| Doxycycline Hyclate | 11 | $138 |
| Mupirocin | 18 | $113 |
| Clotrimazole | 11 | $104 |
Paid to pharmacies, not to this prescriber.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.